PI
DNLI icon

Putnam Investments’s Denali Therapeutics DNLI Stock Holding History

Putnam Investments’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,044
Closed -$1.97M – 1151
2022
Q3 		$1.97M Sell
64,044
-232
-0.4% -$7.54K ﹤0.01% 731
2022
Q2 		$1.89M Buy
64,276
+333
+0.5% +$8.72K ﹤0.01% 756
2022
Q1 		$2.06M Sell
63,943
-12,917
-17% -$444K ﹤0.01% 793
2021
Q4 		$3.43M Buy
76,860
+5,159
+7% +$244K ﹤0.01% 654
2021
Q3 		$3.62M Sell
71,701
-17
-0% -$958 0.01% 629
2021
Q2 		$5.63M Buy
71,718
+98
+0.1% +$6.06K 0.01% 490
2021
Q1 		$4.09M Buy
71,620
+25,538
+55% +$1.71M 0.01% 542
2020
Q4 		$3.86M Buy
+46,082
New +$2.79M 0.01% 539

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Putnam Investments's DNLI Position: Q4 2022 in Review

Putnam Investments sold out of Denali Therapeutics (DNLI) in Q4 2022, closing a stake of 64,044 shares — an estimated $1.97M sold.

Putnam Investments first reported a position in DNLI in Q4 2020 and held it in 8 quarters. The position peaked at $5.63M in Q2 2021. 197 funds tracked by Wall St. Rank hold DNLI as of Q4 2022.

  • Putnam Investments reported no remaining Denali Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Putnam Investments sold 64,044 Denali Therapeutics shares in Q4 2022, an estimated $1.97M.
  • Putnam Investments first reported a position in Denali Therapeutics in Q4 2020 and held it in 8 quarters.
  • Putnam Investments's Denali Therapeutics position peaked at $5.63M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2022.

Based on Putnam Investments's 13F filing for Q4 2022, filed 14 Feb 2023.